Preview | Issue Date | Title | Author(s) | Access |
![Oxycodonenaloxone.naxolone versus tapentadol in real world chronic non‑cancer pain.pdf.jpg](/retrieve/6dff66a3-3891-4c74-9646-8c79f0d0e88e/Oxycodonenaloxone.naxolone%20%20versus%20tapentadol%20in%20real%20world%20chronic%20non%e2%80%91cancer%20pain.pdf.jpg) | 2022 | Oxycodone/naloxone versus tapentadol in real‑world chronic non‑cancer pain management: an observational and pharmacogenetic study | Barrachina, Jordi; Margarit, Cesar; Muriel, Javier; López‑Gil, Santiago; López Gil, Vicente; Vara-González, Amaya; Planelles, Beatriz; Inda, María del Mar; Morales, Domingo; Peiró, Ana María | ![](/image/openAccess.png) |
![OPRM1 influence on and effectiveness of an individualized.pdf.jpg](/retrieve/f0912f0d-190d-4252-9401-6e74eb01cbdc/OPRM1%20influence%20on%20and%20effectiveness%20of%20an%20individualized.pdf.jpg) | 2018 | OPRM1 influence on and effectiveness of an individualized treatment plan for prescription opioid use disorder patients | Muriel, Javier; Margarit, César; Planelles, Beatriz; Serralta, María J.; Puga, Carmen; Inda, María del Mar; Cutillas, Esperanza; Morales, Domingo; Horga, José F. | ![](/image/closedAccess.png) |
![Sex-Differences in Pain and Opioid Use Disorder Management.pdf.jpg](/retrieve/cdaa89cd-f9f5-4e9f-841d-30bf0c32ba97/Sex-Differences%20in%20Pain%20and%20Opioid%20Use%20Disorder%20Management.pdf.jpg) | 2022 | Sex-Differences in Pain and Opioid Use Disorder Management: A Cross-Sectional Real-World Study | Escorial, Mónica; Muriel, Javier; César, Margarit; Laura, Agulló; Domingo, Morales; Peiró, Ana | ![](/image/openAccess.png) |
![Pharmacogenetic Guided Opioid Therapy Improves Chronic.pdf.jpg](/retrieve/1772878b-270e-4cd7-bc03-a7cb5fee6471/Pharmacogenetic%20Guided%20Opioid%20Therapy%20Improves%20Chronic.pdf.jpg) | 2023 | Pharmacogenetic Guided Opioid Therapy Improves Chronic Pain Outcomes and Comorbid Mental Health: A Randomized, Double-Blind, Controlled Study | Agulló, Laura; Aguado, Isidro; Muriel, Javier; Margarit, César; Gómez, Alba; Escorial, Mónica; Sánchez, Astrid; Fernández, Alicia; Peiró, Ana | ![](/image/openAccess.png) |
![Clinical prediction of opioid use disorder in chronic pain patients. A cohort-retrospective study with a pharmacogenetic approach.pdf.jpg](/retrieve/a558ddfe-37b5-4dd4-8872-0167dd3ecf23/Clinical%20prediction%20of%20opioid%20use%20disorder%20in%20chronic%20pain%20patients.%20A%20cohort-retrospective%20study%20with%20a%20pharmacogenetic%20approach.pdf.jpg) | 12-Apr-2024 | Clinical prediction of opioid use disorder in chronic pain patients: a cohort-retrospective study with a pharmacogenetic approach | Escorial, Mónica; Muriel, Javier; Agulló, Laura; Zandonai, Thomas; Margarit, César; Morales, Domingo; Peiró, Ana | ![](/image/openAccess.png) |
![Oxycodonenaloxone - naloxone versus tapentadol in real-world chronic non-cancer pain management.an observational and pharmacogenetic study.pdf.jpg](/retrieve/49e3f51c-59c2-43d1-9d15-6d348e3d5cf2/Oxycodonenaloxone%20-%20naloxone%20versus%20tapentadol%20in%20real-world%20chronic%20non-cancer%20pain%20management.an%20observational%20and%20pharmacogenetic%20study.pdf.jpg) | Jun-2022 | Oxycodone/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study | Barrachina, Jordi; Margarit, César; Muriel, Javier; López‑Gil, Santiago; López Gil, Vicente; Vara-González, Amaya; Planelles, Beatriz; Inda, María del Mar; Morales, Domingo; Peiró, Ana | ![](/image/openAccess.png) |
![Long-term deprescription in chronic pain and opioid use disorder patients. Pharmacogenetic and sex differences.pdf.jpg](/retrieve/442d251d-8781-4a09-b495-e3bbda10e4df/Long-term%20deprescription%20in%20chronic%20pain%20and%20opioid%20use%20disorder%20patients.%20Pharmacogenetic%20and%20sex%20differences.pdf.jpg) | 18-Nov-2022 | Long-term deprescription in chronic pain and opioid use disorder patients: Pharmacogenetic and sex differences | Muriel, Javier; Escorial, Mónica; Margarit, César; Barrachina, Jordi; Carvajal, Cristian; Morales, Domingo; Peiró, Ana | ![](/image/openAccess.png) |
![CYP2D6 Genotype and Pharmacovigilance Impact on Autism Spectrum Disorder. A Naturalistic Study with Extreme Phenotype Analysis.pdf.jpg](/retrieve/78002e9d-ad29-4c4a-8e05-a953980ab181/CYP2D6%20Genotype%20and%20Pharmacovigilance%20Impact%20on%20Autism%20Spectrum%20Disorder.%20A%20Naturalistic%20Study%20with%20Extreme%20Phenotype%20Analysis.pdf.jpg) | 3-Jul-2023 | CYP2D6 Genotype and Pharmacovigilance Impact on Autism Spectrum Disorder: A Naturalistic Study with Extreme Phenotype Analysis | Ballester, Purificación; Espadas, Cristina; Almenara, Susana; Barrachina, Jordi; Muriel, Javier; Ramos, Enrique; Toral, Natalia; Belda, César; Peiró, Ana | ![](/image/openAccess.png) |
![Impact of CYP2D6 genotype on opioid use disorder deprescription an observational prospective study in chronic pain with sex-differences.pdf.jpg](/retrieve/ff607586-26c5-4511-a50c-c94782d71227/Impact%20of%20CYP2D6%20genotype%20on%20opioid%20use%20disorder%20deprescription%20an%20observational%20prospective%20study%20in%20chronic%20pain%20with%20sex-differences.pdf.jpg) | 2023 | Impact of CYP2D6 genotype on opioid use disorder deprescription: an observational prospective study in chronic pain with sex-differences | Muriel, Javier; Barrachina, Jordi; Del Barco, Guillermo; Carvajal, Cristian; Escorial, Mónica; Margarit, César; Ballester, Purificación; Peiró, Ana María | ![](/image/openAccess.png) |
![CYP2D6 phenotypes and opioid metabolism. the path to personalised analgesia.pdf.jpg](/retrieve/8a3fbbc5-ffc9-46b8-b233-5a18818cb254/CYP2D6%20phenotypes%20and%20opioid%20metabolism.%20the%20path%20to%20personalised%20analgesia.pdf.jpg) | Apr-2022 | CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia | Ballester, Purificación; Muriel, Javier; Peiró, Ana | ![](/image/closedAccess.png) |